MétaCan
Menu
Back to cohort
Record W2147048440 · doi:10.1212/wnl.0b013e318228bf11

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

2011· article· en· W2147048440 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

fundA Canadian funder is recorded on the work.
no affNo Canadian affiliation: this work is invisible to an affiliation-only frame.
No Canadian affiliation. An affiliation-only frame, the usual design, would never have seen this work. It is one of the works that make the case for inverting the frame.

Bibliographic record

VenueNeurology · 2011
Typearticle
Languageen
FieldMedicine
TopicLipoproteins and Cardiovascular Health
Canadian institutionsnot available
FundersNational Institute of Neurological Disorders and StrokeNational Institute of Mental HealthHealth Sciences, University of ArizonaNational Institute on AgingMedical Center, University of RochesterUniversity of California, IrvineUniversity of California, San DiegoUniversity of California, DavisMitsubishi Tanabe Pharma CorporationElanAstraZenecaGenentechUniversity of OxfordBaxter InternationalLewy Body Dementia AssociationNational Center for Research ResourcesNational Alliance for Research on Schizophrenia and DepressionMyriad GeneticsSUNY Downstate Medical CenterMarinus PharmaceuticalsGeorgetown UniversityDemensförbundetOtsuka PharmaceuticalNational Institutes of HealthBioMarin PharmaceuticalAvid RadiopharmaceuticalsUniversity of PittsburghUniversity of California, Los AngelesPfizerUniversity of WashingtonU.S. Department of DefenseAmerican Health Assistance FoundationEli Lilly and CompanyState University of New YorkUniversity of PennsylvaniaUniversity of South CarolinaAstellas PharmaUniversity of Southern CaliforniaEisaiMedpaceBrown UniversityDaiichi Sankyo EuropeYale UniversityAstellas Foundation for Research on Metabolic DisordersDainippon Sumitomo PharmaEmory UniversityAlzheimer's AssociationBrigham and Women's HospitalYork UniversityUniversity of RochesterNorthwestern UniversityGlaxoSmithKlineShireForest LaboratoriesBristol-Myers SquibbSanofiCase Western Reserve UniversityAmerican Federation for Aging ResearchRush UniversityAmgen
KeywordsSimvastatinMedicinePlaceboRandomized controlled trialDouble blindAlzheimer's diseaseDiseaseInternal medicinePathologyAlternative medicine

Abstract

fetched live from OpenAlex

Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG - CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, supporting the hypothesis that statin therapy is useful in the treatment of AD. Objective: To determine if the lipid-lowering agent simvastatin slows the progression of symptoms in AD. Methods: This randomized, double-blind, placebo-controlled trial of simvastatin was conducted in individuals with mild to moderate AD and normal lipid levels. Participants were randomly assigned to receive simvastatin, 20 mg/day, for 6 weeks then 40 mg per day for the remainder of 18 months or identical placebo. The primary outcome was the rate of change in the Alzheimer's Disease Assessment Scale–cognitive portion (ADAS-Cog). Secondary outcomes measured clinical global change, cognition, function, and behavior. Results: A total of 406 individuals were randomized: 204 to simvastatin and 202 to placebo. Simvastatin lowered lipid levels but had no effect on change in ADAS-Cog score or the secondary outcome measures. There was no evidence of increased adverse events with simvastatin treatment. Conclusion: Simvastatin had no benefit on the progression of symptoms in individuals with mild to moderate AD despite significant lowering of cholesterol. Classification of evidence: This study provides Class I evidence that simvastatin 40 mg/day does not slow decline on the ADAS-Cog. Aβ= : amyloid β peptide; AChE= : acetylcholinesterase; AD= : Alzheimer disease; ADAS-Cog= : Alzheimer's Disease Assessment Scale–cognitive portion; ADCS= : Alzheimer's Disease Cooperative Study; ADCS-ADL= : Alzheimer's Disease Cooperative Study Activities of Daily Living; ADCS-CGIC= : Alzheimer's Disease Cooperative Study Clinical Global Impression of Change; ADCS-RUI= : Alzheimer's Disease Cooperative Study Resource Use Instrument; ALT= : alanine aminotransferase; AST= : aspartate aminotransferase; ATP= : Adult Treatment Panel; CRP= : C-reactive protein; GEE= : generalized estimating equation; HDL= : high-density lipoprotein; HMG-CoA= : 3-hydroxy-3-methylglutaryl coenzyme A; ITT= : intent-to-treat; LDL= : low-density lipoprotein; MMSE= : Mini-Mental State Examination; NPI= : Neuropsychiatric Inventory; QOL= : quality of life

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.017
Threshold uncertainty score0.530

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.053
GPT teacher head0.305
Teacher spread0.252 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it